At the same time, increased SET protein levels correlated with worse clinical outcomes.10, 11 Studies on tumor samples from patients with hepatocellular carcinoma, pancreatic cancer, and metastatic colorectal cancer, respectively, verified that SET overexpression is tumor specific and contributes to tumor progression.12, 13, 14 Janghorban et al15 found that about 50% of breast cancer cell lines showed overexpression of SET by RNA‐seq and Western blotting across all tumor subtypes, which was further confirmed using primary human breast tumor samples with patient‐matched adjacent normal tissue. The gene discussed is SET; the disease is breast carcinoma.